

Christoph Wanner, M.D.

Professor of Medicine, University of Würzburg
Department of Clinical Research and Epidemiology
Renal Research Unit, University Hospital of Würzburg
Am Schwarzenberg 15, 97078 Würzburg (Germany)
Tel.: +49-1715095067, E-mail: wanner_c@ukw.de

Curriculum vitae

21.03.1957 Born at Bad Mergentheim (Germany)
1976-1982 Education in Medicine at the
Universities of Ferrara (Italy), Berlin and Würzburg (Germany)
1982 Subinternships, Anaesthesia & Int Med,
Singapore and Zürich (Swiss)
1983 Thesis (degree of M.D.) at the Department of Medicine,
University of Würzburg (Germany)
1983-1990 Residency and Fellowship in Internal Medicine and Nephrology
at the Department of Medicine, Division of Nephrology,
University of Freiburg (Germany)
1990 Habilitation (equivalent to PhD), Faculty member, Assistant
Professor at the Department of Medicine, Division of Nephrology,
University of Freiburg (Germany)
1991 German Board of Internal Medicine Examination
1992 National Institutes of Health, National Heart, Lung, and
Blood Institute, Molecular Disease Branch
1993 German Board of Internal Medicine/Nephrology Examination
1994-2023 Professor of Medicine, University of Würzburg (Germany),
Department of Medicine, Head, Division of Nephrology,
University Hospital of Würzburg (Germany)
2003-2009 Director, Clinical Trial Service Unit,
University Hospital of Würzburg (Germany)
4/2023- Senior Professor of Medicine, University of Würzburg (Germany),
Dept of Clinical Research and Epidemiology, Renal Research Unit,
University Hospital of Würzburg (Germany)
8/2023- Visiting Professor, University of Oxford (United Kingdom),
Nuffield Department of Population Health, Clinical Trial
Service Unit (CTSU)

September 17, 2025



Research Profile

Scientific Areas of Interest

1990-	Role of lipids in the progression of renal disease; glomerulosclerosis & atherosclerosis in CKD and kidney failure
1998-2005	Principal investigator of the 4D study
2003-2011	Central Europe Coordinator of SHARP
2011-2017	Germany Coordinator of REVEAL
1996-	Elucidation of the inflammatory response syndrome and biomarkers in diabetic kidney disease, CKD and kidney failure
2000-	Fabry disease and Fabry nephropathy
2008-	Cardiovascular and kidney outcomes in Type 2 Diabetes
Since 2010	Steering committees of BEACON, EMPA-REG OUTCOME, CARMELINA, EMPA-KIDNEY & ASCEND studies
2009-	Cardio-Renal Crosstalk and heart failure. Since 2016 Steering committee of EMPEROR studies.

Membership in scientific committees / boards / societies

Leadership in Professional Societies

1998-2007	Councilor, German Society of Nephrology
1998-2007	Chairman, Kuratorium of the Germany Society of Nephrology
2003-2007	President, German Kidney Foundation
2006-2009	Vice-Chairman, German Assoc. of Clinical Nephrology (GACN)
2006-09 &	
2018-21	Councilor, European Renal Association – ERA-EDTA
2008-2014	Secretary, President elect and President, International Society of Renal Nutrition & Metabolism (ISRNM)
2009-2015	Chairman, ERA-EDTA Renal Registry
2019-2020	President elect, European Renal Association – ERA-EDTA
2020-2024	President, European Renal Association – ERA
6/2024-	Past President, ERA

Membership in Professional Societies since 1984

1984/86	German Society of Nephrology (DGfN) formerly GfN & GACN
1985	American Society of Nephrology (ASN)
1986	International Society of Nephrology (ISN)
1987	Int Soc Nutrition & Metabolism in Renal Disease (ISRNM)
1987	US National Kidney Foundation (NKF)
1988	ERA (formerly ERA-EDTA)

Editorial scientific activities

1995-2017	Nephrology Dialysis Transplantation (Editorial Board)
1997-2002	Kidney & Blood Pressure Research (Editorial Board)
1999-2002	Journal of the American Society of Nephrology (Editorial Board)
2002-2004	American Journal Kidney Disease (Associate Editor)
2003-2008	Editor-in-chief: Kidney & Blood Pressure Research
2003-2010	Associate Editor: Journal of Renal Nutrition
2002-2014	Editorial Board: Nephron
2000-2017	Subject Editor: Nephrology Dialysis Transplantation
2001-2013	Editorial Board: Kidney International
2007-2018	Journal of the American Society of Nephrology (Editorial Board)
2000-2015	Editorial Board: Clinical Nephrology
2005-	Editorial Board: Port J of Nephrology and Hypertension
2006-	Editorial Board: Current Opinion in Nephrology & Hypertension
2006-	Editorial Board: Folia Biologica – J Cell Mol Biol
2017-2020	Associate Editor: Clinical Journal of the Am Soc Nephrology
2011-2019	Editor-in-chief: Journal of Renal Nutrition
2022-2023	Associate Editor: Clinical Kidney Journal

Advisory board member and review activities

- 1994- Deutsche Forschungsgemeinschaft (DfG),
Bundesministerium für Bildung und Forschung (BMBF)
- 2000-2006 European Best Practice Guidelines (EBPG)
– Haemodialysis (Part I & II)
- 2000-2006 K/DOQI, Kidney Disease Outcomes Quality Initiative:
▶ Clinical practice guidelines on managing dyslipidemias in CKD,
work group member
▶ Clinical practice guidelines on prevention of diabetic nephropathy,
work group member
- 2003-2019 KDIGO, Kidney Disease improving Global Outcomes
▶ Executive Board of Directors (2003-2005, 2011-2017)
▶ Board of Councilors (2007-2011)
▶ Co-Chair-Guidelines on dyslipidemia in CKD (2010-2013)
▶ Co-Chair, Controversy conference on Fabry Nephropathy (2015)
and Arrhythmias (2016)
- 2003-2009 Member, ERA-EDTA Registry
- 2005- Member, Cholesterol Treatment Trialists' (CTT) Collaboration
- 2009-2010 Reviewer, European FP7 Framework & Agence de Recherche
- 2013-2015 Scientific Committee, ESPN/ERA-EDTA Registry
- 2015 Reviewer, European Research Council (ERC)
- 2016-2019 Board Evaluator, Swiss National Science Foundation (SNSF)
- 2022- Member, c-SMART Collaboration

International Education and Teaching

- 2000-2007 Courses on "How to write a paper" – "How to read and review a
paper" (World Congress of Nephrology, Berlin, Oxford/UK,
Austria/Innsbruck-Salzburg)
- 2002-2009 Lecturer - Junior Scientific Masterclass – Introduction to Medical
Research / Mannheim Faculty of Medicine
- 2004-2015 Lecturer: ERA-EDTA: Introductory Courses on Epidemiology –
Observational studies; RCTs
- 2006 ERA-EDTA Annual Congress: Epidemiology in Kidney Disease?
- 2006-2008 ASN Course – Applying the Principles of Epidemiology and
Biostatistics (Lecturer)
- 2015 ERA-EDTA (London): Lancet Session – How to write a paper

Selected Official Invitations – International Societies (since 2005)

06/2005	JSN and JSDT, Yokohama
2005/17	ISN, WCN, Singapore, Mexiko City
09/2005	French-speaking Soc of Dialysis & Neph Soc, Clermont-Ferrand
10/2006	Czech & Belgium Societies of Hypertension, Marianske Lazne
11/2006	Turkish Society of Nephrology (TSN), Antalya
12/2006	Swiss Society of Nephrology, Solothurn
04/2007	US National Kidney Foundation Spring Clinical Meeting, Orlando
05/2007	Polish Society of Nephrology, Wisla
09/2007	Int Soc Blood Purification (ISBP), Prague, Czech Republic
02/2008	Spanish Society of Nephrology, Madrid
11/2008	American Soc Nephrol (ASN), Philadelphia
11/2008	American Heart Association, New Orleans
06/2009	Polish Society of Nephrology, Warsaw
11/2009	Swedish Societies of Medicine & Nephrology, Stockholm
06/2011	Polish Society of Nephrology, Rzeszów
09/2011	Shanghai Society of Nephrology, China
09/2011	Italian Society of Nephrology (SIN), Genova
2012/13	ASN, San Diego/Atlanta
04/2014	Philippine Society of Nephrology, Manila
06/2014	Baltic Societies of Nephrology, Vilnius, Lithuania
07/2014	Japanese Society of Nephrology (JSN), Yokohama
09/2014	Spanish Society of Nephrology, Barcelona
05/2015	American Society of Transplantation, Philadelphia
12/2015	Czech Society of Nephrology, Prague
12/2015	International Diabetes Federation - World Congress, Vancouver
05/2016	European Renal Association (ERA-EDTA), Vienna
06/2016	American Diabetes Association (ADA), New Orleans
08/2016	European Society Cardiology (ESC), Rome, Italy
09/2016	European Assoc of Studies in Diabetes, Munich, Germany
17/18/19	ASN, New Orleans/San Diego/Washington DC
04/2018	Korean Endocrine Society (KES), Seoul
05/2018	American Diabetes Association (ADA), New Orleans
06/2018	Int. Soc. Renal Nutrition & Metabolism (ISRNM), Genova
06/2018	Japanese Society of Nephrology (JSN), Niigata
10/2018	Japanese Society of Diabetes Complications (JSDC), Tokyo
11/2019	Indian Society of Nephrology (ISN), Chandigarh
10/2019	Chilenian Society of Nephrology, Coquimbo
20/21/22	Virtual multiple: JSN, Hong Kong, Baltic, Hungaria, ISRNM

22/23/24	Hellenic Soc Nephrology, Thessaloniki, Heraklion, Athens
2022	Latvian Soc Nephrology, Riga
20/22/23	Turkish Soc Nephrology (TSN), Istanbul, Antalya, Antalya
2023	Emirates Soc Nephrology & Transplantation, Dubai
23/24/25	JSN, Yokohama
23/24/25	ASN, Philadelphia, San Diego, Houston
2025	Mexican Soc Nephrology, Merida

Awards

1985	Award for Clinical Investigation, American Medical Association
1991	Merck Award for Clinical Investigation – Hypertension
2006-	Visiting Professor (standing), Charles University Prague
2007	International Distinguished Medal of the US NKF
2011	Honorary Member, Polish Society of Nephrology
2012	Doctor Honoris Causa, Charles University Prague
2016	Visiting Professor, Harvard Medical School – MGH, BWH, BID MC
2016	ERA-EDTA Outstanding Clinical Contributions to Nephrology
2016	„Wennerström Lecture“ of Göteborg Sahlgrenska University
2018	Honorary Int Member, Japanese Society of Nephrology
2018	Thomas Addis Medal, Int Society Renal Nutrition Metabolism
2018	Franz-Volhard-Medaille, DGfN
2018	Outstanding foreign Investigator Award, KSDC
2018	Visiting Professor, Vanderbilt University
2020	Richard Yu Award, HongKong Society of Nephrology
2020	Honorary Member, Hungarian Society of Nephrology
2023	Doctor Honoris Causa, University of Thessaloniki

Organization of international scientific meetings

2002	President, V th International Congress of Uraemic Toxicity
2010	President, XLVII ERA-EDTA Congress - II DGfN Congress
2014	President, 17 th Int Soc Renal Nutrition & Metabolism Congress
2021-2024	President, European Renal Association 59th-62nd Congress
2024-2025	Past President ERA

Publications

Publications in the respective field

- ▶ Hirsch index 125 (Web of Science), 160 (Google Scholar); cumulative IF >4000; >70.000 citations (>12.000 in 2023+2024); Clarivate highly cited researcher 2019, 2023 and 2024
- ▶ >1000 citations in pubmed (>30 in NEJM, Lancet & JAMA), >50 books & book chapters
- ▶ Guest Editor in Kidney Int, Clin Therapeutics, KBPR & NDT

3 best cited publications

Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005;353:238-248 (>2000 citations)

Zinman B, **Wanner C**, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen O-E, Woerle HJ, Broedl UC, Inzucchi S. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. *New Engl J Med* 2015;373:2117-2128 (>4500 citations)

Wanner C, Inzucchi S, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen O-E, Woehrle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. *New Engl J Med* 2016;375:323-334 (>2000 citations)

12 selected updated publications

1. Walz G, Budde K, Mannaa M, Nürnberger J, **Wanner C** et al., Everolimus in patients with autosomal dominant polycystic kidney disease. *N Engl J Med* 2010;363:830-840
2. Baigent C, Landray M, Reith C, Emberson J, Wheeler DC, Tomson C, **Wanner C** et al. SHARP Investigators. The effect of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a placebo controlled trial. *Lancet* 2011;377:2181-219
3. Thadani R, Appelbaum E, Pritchett Y, Chang Y, Wegner J, Bhan I, Agarwal R, Zoccali C, **Wanner C**, et al. Vitamin D therapy and cardiac structure, function, and cardiovascular events. *JAMA* 2012;307:674-684

4. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, **Wanner C**, Wittes J, Wrolstad D, Chertow GM; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. *N Engl J Med* 2013;369:2492-2503
5. **Wanner C**, Amman K, Shoji T. The heart and vascular system in dialysis. *Lancet* 2016;388:276-284
6. HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease *New Engl J Med* 2017; 377:1217-1227
7. **Wanner C**, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. *Circulation* 2018;137:119-129
8. **Wanner C**, Heerspink HJL, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, Hantel S, Woerle HJ, Broedle UC, von Eynatten M, Groop PH. Empagliflozin and kidney function decline in patients with type 2 diabetes. A slope analysis from the EMPA-REG OUTCOME trial. *J Am Soc Nephrol* 2018;29:2755-2769
9. Packer M, Anker SD, Butler J et al, **Wanner C**, Zannad F. EMPEROR-Reduced trial. Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 2020;383:1413-1424
10. Singh AK, Carroll K, McMurray JJV et al, **Wanner C**, Perkovic V. ASCEND-ND Study Group. Daprodustat for the treatment of anemia in patients not undergoing dialysis. *N Engl J Med* 2021;385:2313-2324
11. Herrington WG, Staplin N, **Wanner C** et al, Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2023;388:117-127
12. Herrington WG, Staplin N, Agrawal N, **Wanner C** et al. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2025;392:777-787